Anti-PD1 therapy has been particularly effective in virtually every cutaneous malignancy in which this therapy class has been evaluated formally, likely in part due to the stigmata of a high ultraviolet (UV)-mutational burden that is common across these cancer types.[1–3] In contrast, reports from clinical trials with pembrolizumab or nivolumab as either monotherapy or in combination with ipilimumab have shown only modest antitumor activity in unselected advanced sarcomas, with response rates of roughly 10–20% when including all histological subtypes.[4–7]. This evidence concerns the gene PDCD1 and sarcoma.